智通财经APP获悉，港股恒生指数涨0.18%，涨47点，报25848点；恒生科技指数跌0.42%；港股早盘成 交872亿港元。 东岳集团(00189)盘中涨近4%，26年配额发布，有望支撑HFCs供需偏紧。 新股上市，诺比侃(02635)首挂上市，涨超330%；轻松健康（02661）涨超140%；翰思艾泰-B(03378)破 发跌超40%； 黄金现货+期货价格再创历史新高。理事建议美联储采取更鸽派立场，机构指黄金配置价值依旧突出。 山东黄金(01787)涨6%；招金矿业(01818)涨4%。 今早碳酸锂期货2605合约一度涨4%，最高见118580元/吨。锂业股延续涨势。赣锋锂业(01772)涨超 4%，天齐锂业(09696)涨4%。 力勤资源(02245)再涨超3%，印尼供应扰动不断发酵，镍供给过剩情况有望得到缓解。 昭衍新药(06127)涨超5%，上游实验猴供给端紧张，公允价值变动有望贡献利润。 国泰航空(00293)涨超7%，国泰航空预计十年来首次实现连续年度盈利增长。 华芢生物-B(02396)上市次日再挫逾17%，较招股价已跌逾四成。 药捷安康-B(02617)跌超15%，今日迎基石解禁，累计解禁股 ...

Core Viewpoint - The stock price of Zhaoyan New Drug (06127) increased by 5.17%, currently trading at HKD 22.38, with a transaction volume of HKD 121 million, indicating a recovery in demand for preclinical CRO clients and a tight supply of experimental monkeys [5]. Group 1: Market Dynamics - There is a resurgence in demand for preclinical CRO services, particularly for new technology platforms such as large molecules (monoclonal antibodies, ADCs), small nucleic acids, peptides, and cell gene therapies, which require the use of macaques for safety evaluation tests [5]. - The price of 3-5 year old macaques has risen to HKD 140,000 each, reflecting a supply-demand imbalance in the market, which further supports the recovery of domestic innovative drug research and development [5]. Group 2: Financial Implications - According to estimates from Founder Securities, if Zhaoyan New Drug accounts for an average fair value of HKD 84,900 per monkey in 2024, and the price increases to HKD 140,000 by Q4 2025, the estimated new fair value addition for 2025 could be approximately HKD 220 million, based on a known population of 23,200 monkeys and an output rate of 17% [5].

每经AI快讯，昭衍新药(06127.HK)涨超5%，截至发稿涨5.17%，报22.38港元，成交额1.16亿港元。 （文章来源：每日经济新闻） ...

Core Viewpoint - The stock of Zhaoyan New Drug (06127) has risen over 5%, currently trading at 22.38 HKD with a transaction volume of 116 million HKD, driven by a recovery in demand for preclinical CRO clients and a tight supply of experimental monkeys [1] Group 1: Market Dynamics - Demand for preclinical CRO services is recovering, particularly for new technology platforms such as large molecules (multi-antibodies, ADC), small nucleic acids, peptides, and cell gene therapies, which require macaques for safety evaluation tests [1] - The price of experimental macaques has increased significantly, with 3-5 year old macaques now priced at 140,000 RMB each, indicating a supply-demand imbalance in the market [1] Group 2: Financial Implications - According to estimates from Founder Securities, if the average price of experimental macaques is accounted for at 84,900 RMB each in 2024 and increases to 140,000 RMB by Q4 2025, the estimated new fair value contribution for Zhaoyan New Drug in 2025 could be approximately 220 million RMB, based on a known supply of 23,200 macaques and an estimated output rate of 17% [1]

Core Viewpoint - The stock of Zhaoyan New Drug (603127) has increased by over 5%, currently trading at 22.38 HKD with a transaction volume of 116 million HKD, indicating a positive market response to recent developments in the preclinical CRO sector [1] Group 1: Market Demand and Supply Dynamics - There is a recovery in demand from preclinical CRO clients, while the supply of experimental monkeys is tight, leading to increased prices [1] - The price of the food crab monkey, essential for safety evaluation tests in drug development, has risen to 140,000 RMB per monkey, reflecting a supply-demand imbalance [1] Group 2: Impact on Drug Development - New technology platforms such as large molecules (multi-antibodies, ADC), small nucleic acids, peptides, and cell gene therapies require food crab monkeys for safety evaluation, highlighting the importance of this resource in innovative drug development [1] - The increase in monkey prices will directly contribute to profit through fair value changes, supporting the recovery of domestic innovative drug research and development [1] Group 3: Financial Projections - According to estimates from Founder Securities, if the average price of experimental monkeys is accounted for at 84,900 RMB in 2024 and increases to 140,000 RMB by Q4 2025, the estimated new fair value addition for Zhaoyan New Drug in 2025 could be approximately 220 million RMB, based on a known population of 23,200 monkeys [1]

Group 1 - The CRO sector is under pressure, with notable declines in stock prices: Kanglong Chemical down 4.32% to HKD 21.24, Zhaoyan New Drug down 3.29% to HKD 21.16, Kylin Pharmaceutical down 2.31% to HKD 78.15, and Weiya Bio down 1.98% to HKD 1.98 [1] - The revised U.S. Biodefense Act was passed in the Senate with a vote of 77 to 20 and is set to be signed into law by the President, marking a significant legislative step [1] - The Biodefense Act has been a key factor in suppressing the valuation of the CXO sector over the past two years, but the final version is considered relatively moderate compared to the initial draft, as it does not specifically name companies [1] Group 2 - With the Federal Reserve entering a rate-cutting phase, there is potential for marginal improvement in global biopharmaceutical investment and financing [1] - The implementation of the Biodefense Act is expected to lead to a dual recovery in both performance and valuation for the CXO sector [1]

Group 1 - The CRO sector is under pressure, with notable declines in stock prices: Kanglong Chemical down 4.32% to HKD 21.24, Zhaoyan New Drug down 3.29% to HKD 21.16, Kylin Pharmaceutical down 2.31% to HKD 78.15, and Weiya Bio down 1.98% to HKD 1.98 [1][1][1] - The revised U.S. Biodefense Law, part of the 2026 National Defense Authorization Act (NDAA), has passed the Senate with a vote of 77 to 20 and is expected to be signed by the President, completing the legislative process [1][1][1] - According to Cinda Securities, the Biodefense Law has been a significant factor in suppressing the valuation of the CXO sector over the past two years, but the final version is relatively moderate compared to the initial draft, as it does not specifically name companies [1][1][1] Group 2 - With the Federal Reserve entering a rate-cutting cycle, global biopharmaceutical investment and financing are expected to improve marginally [1][1][1] - The implementation of the Biodefense Law is anticipated to lead to a dual recovery in both performance and valuation for the CXO sector [1][1][1]

Group 1 - CRO concept stocks are under pressure, with notable declines in share prices: Kanglong Chemical down 4.32% to HKD 21.24, Zhaoyan New Drug down 3.29% to HKD 21.16, Kelaiying down 2.31% to HKD 78.15, and Weiya Bio down 1.98% to HKD 1.98 [1] - The revised U.S. Biodefense Law was passed in the Senate with a vote of 77 in favor and 20 against, completing the main legislative process and is set to be signed by the President [1] - According to Xinda Securities, the Biodefense Law has been a significant factor suppressing the valuation of the CXO sector over the past two years, but the final version is relatively mild compared to the initial draft, as it does not name specific companies [1] Group 2 - With the Federal Reserve entering a rate-cutting phase, global biopharmaceutical investment and financing are expected to improve marginally [1] - The implementation of the Biodefense Law is anticipated to lead to a dual recovery in performance and valuation for the CXO sector [1]

Investment Rating - The industry investment rating is "Overweight" [1] Core Views - The biopharmaceutical investment and financing environment has shown significant recovery since the second half of 2025, with a total financing amount of USD 30.32 billion from July to November 2025, representing a year-on-year increase of 30.90% [4] - The number of new drug IND applications stabilized in 2025, with approximately 1,897 applications from January to November, reflecting a year-on-year growth of about 7.91% [4] - The demand for CRO services has shown a clear turning point, and the report continues to recommend opportunities in the innovative drug industry chain (CXO + research services) for 2026 [4] Summary by Sections Industry Performance - The biopharmaceutical sector experienced a decline of 0.14% in the third week of December 2025, outperforming the CSI 300 index by 0.14 percentage points, ranking 22nd among 31 sub-industries [7][14] - The offline pharmacy sector saw the highest increase, rising by 5.59%, while the chemical preparation sector had the largest decline at 2.1% [18][22] Investment Opportunities - The report highlights the strong performance of leading CXO and research service companies, with many exceeding earnings expectations. Companies like WuXi AppTec and Tigermed have raised their earnings guidance for 2025 [5] - The report recommends a valuation switch opportunity for leading CXO and research service companies, given the continuous improvement in demand [5] Clinical Research Organizations (CRO) - There has been a notable improvement in orders for preclinical and clinical CROs, with expectations for significant improvements in financial statements for 2026 [6] - The report anticipates that the market demand will continue to focus on leading companies as the capacity of clinical CROs is expected to be streamlined [6] Monthly and Weekly Recommendations - The report recommends a monthly investment portfolio including companies such as Sanofi, Innovent Biologics, and others, focusing on innovative drug opportunities and valuation switch [8]

Group 1 - The top three companies with the highest short positions are Vanke Enterprises (02202), COSCO Shipping Holdings (01919), and Heng Rui Medicine (01276), with short ratios of 19.04%, 17.09%, and 15.18% respectively [1][2] - The companies with the largest absolute increase in short positions are Zhaoyan New Drug (06127), Lens Technology (06613), and China Everbright Holdings (00165), with increases of 2.08%, 1.68%, and 1.46% respectively [1][2] - The companies with the largest absolute decrease in short positions are ZTE Corporation (00763), Nuo Cheng Jian Hua (09969), and Yi Mai Tong (02192), with decreases of -3.12%, -2.21%, and -1.70% respectively [1][2] Group 2 - The top ten companies with the highest short ratios include Vanke Enterprises (02202) at 19.04%, COSCO Shipping Holdings (01919) at 17.09%, and Heng Rui Medicine (01276) at 15.18% [2] - The companies with the most significant increase in short ratios include Zhaoyan New Drug (06127) from 3.50% to 5.57%, Lens Technology (06613) from 3.07% to 4.75%, and China Everbright Holdings (00165) from 2.04% to 3.51% [2] - The companies with the most significant decrease in short ratios include ZTE Corporation (00763) from 17.63% to 14.51%, Nuo Cheng Jian Hua (09969) from 5.19% to 2.97%, and Yi Mai Tong (02192) from 3.06% to 1.36% [2][3]